TIDMNSCI
NetScientific PLC
20 September 2018
NetScientific plc
("NetScientific" or the "Company" or the "Group")
ProAxsis Immunoassays Selected for Large-Scale ERS-Funded BRIDGE
Respiratory trial
- 1,000 patient BRIDGE study to be funded by the European
Respiratory Society
London, UK - 20 September, 2018 - NetScientific plc
("NetScientific", AIM:NSCI), the transatlantic healthcare IP
commercialisation group, announces that its portfolio company
ProAxsis Limited ("ProAxsis") has had two products selected for
inclusion in the BRIDGE study*, a major upcoming clinical trial
funded by the European Respiratory Society (ERS).
The study will employ NEATstik(R) - the first test ever
developed to enable measurement of active neutrophil elastase at
point-of-care - and the ProteaseTag(R) Active NE Immunoassay over 3
years in 1000 patients suffering from bronchiectasis across Europe,
with the purpose of stratifying the clinical population.
Assessments will include microbiome, proteomics, detailed
phenotyping, and imaging, in order to explore new biomarkers and
determine their impact on clinical outcomes.
Commenting on the news, NetScientific's Chief Executive Officer
and ProAxsis' Chairman, Francois R. Martelet, said: "BRIDGE will be
a major respiratory study and we are pleased that the ERS, a
prominent research body, has selected ProAxsis' respiratory
immunoassays for inclusion.
"ProAxsis has demonstrated that active neutrophil elastase can
help identify bronchiectasis patients at highest risk of clinical
exacerbations, so we are excited for the opportunity to explore
this and other potential biomarkers in a large, pan-European
patient population. This decision further validates the use of
these immunoassays in the respiratory field, and we expect to see
this translate into further engagement with pharmaceutical
companies that are active in the area."
NetScientific holds 54% of ProAxsis on a fully diluted
basis.
The full text of the announcement from ProAxsis can be found
below.
*The BRIDGE study - Bronchiectasis Research Involving Databases,
Genomics and Endotyping to match the right treatment to the right
patient. The study is funded by the European Respiratory Society
(ERS).
# # #
For more information, please contact:
NetScientific Tel: +44 (0)20 3514 1800
François R. Martelet,
M.D., CEO
Ian Postlethwaite, CFO
Consilium Strategic Communications Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Chris Welsh netscientific@consilium-comms.com
/ Laura Thornton
Tel: 020 7220 1666
WH Ireland (NOMAD and Broker)
Chris Fielding / Jessica Cave
/ Chris Viggor
ProAxsis assays selected for inclusion in major new ERS-funded
study
Date: 20 September 2018
ProAxsis Limited (www.proaxsis.com), the Belfast-based company
focused on developing new assays for the measurement of active
protease biomarkers of disease, today announces that two of its
products, the ProteaseTag(R) Active NE Immunoassay and NEATstik(R),
the first test to enable measurement of active neutrophil elastase
at point-of-care, have been selected for inclusion in a major
upcoming clinical trial.
The BRIDGE study is a 3-year collaborative study, funded by the
European Respiratory Society (ERS), in which 1000 patients with
bronchiectasis across Europe will be recruited and will have
multiple assessments including microbiome, proteomics, detailed
phenotyping and imaging. The study will explore novel biomarkers
and demonstrate what they can add to clinical practice.
Commenting on the news, Dr David Ribeiro, CEO of ProAxsis, said:
"We're delighted that this group of eminent researchers in the
field of respiratory medicine have chosen to include both the NE
immunoassay and NEATstik(R) in to the protocol of this important
study, and look forward to collaborating with many of the top
bronchiectasis research groups in Europe."
Professor James Chalmers, the Chief Investigator of the BRIDGE
study, added: "Bronchiectasis is a common disabling and
heterogeneous disease that has been neglected in terms of basic and
clinical research. This study aims to explore the clinical,
microbiological, inflammatory and functional heterogeneity of the
disease with the aim of identifying patient endotypes for
stratified medicine. We've previously demonstrated that active
neutrophil elastase can help identify bronchiectasis patients at
highest risk of clinical worsening*, so we're excited about further
exploring this and other potential biomarkers in a large,
pan-European patient population."
Any queries concerning ProAxsis' immunoassay and point-of-care
test for measuring active Neutrophil Elastase, or any requests for
support with measuring other active protease biomarkers using the
Company's proprietary ProteaseTag(R) technology, can be directed to
info@proaxsis.com.
*Chalmers et al (2017) AJRCCM
About NetScientific
NetScientific is a transatlantic healthcare technology group
with an investment strategy focused on sourcing, funding and
commercialising technologies that significantly improve the health
and well-being of people with chronic diseases. For more
information, please visit the website at www.netscientific.net
About ProAxsis Limited:
ProAxsis is developing a range of products for the capture,
detection and measurement of active protease biomarkers of disease.
Its first commercialised immunoassay measures neutrophil elastase,
a leading indicator of infection and inflammation in patients with
Cystic Fibrosis (CF), Chronic Obstructive Pulmonary Disease (COPD)
and bronchiectasis, and an important drug target. The rapid and
easy-to-use tests being developed by ProAxsis incorporate patented
ProteaseTags(R); smart molecules which trap an active protease
within a complex biological sample and enable a visual readout of
its presence. ProteaseTags(R) provide a unique tool to identify and
quantify active protease biomarkers and will assist in the clinical
validation of new therapeutics.
ProAxsis is part of the NetScientific Group and is one of the
Group's core portfolio companies. The company is also supported by
QUBIS, the commercialisation arm of Queens University.
About the BRIDGE study:
The BRIDGE study - Bronchiectasis Research Involving Databases,
Genomics and Endotyping to match the right treatment to the right
patient. The BRIDGE study - Bronchiectasis Research Involving
Databases, Genomics and Endotyping to match the right treatment to
the right patient. The BRIDGE study is a 3-year collaborative
study, funded by the European Respiratory Society (ERS), in which
1000 patients with bronchiectasis across Europe will be recruited
and will have multiple assessments including microbiome,
proteomics, detailed phenotyping and imaging. The study will
explore novel biomarkers and demonstrate what they can add to
clinical practice.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRASFUFLUFASESU
(END) Dow Jones Newswires
September 20, 2018 02:01 ET (06:01 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024